Amedisys Inc (NASDAQ:AMED) was up 6.7% during mid-day trading on Thursday . The company traded as high as $54.81 and last traded at $54.53. Approximately 584,742 shares were traded during trading, an increase of 62% from the average daily volume of 360,618 shares. The stock had previously closed at $51.10.
A number of equities research analysts have recently issued reports on AMED shares. Oppenheimer reiterated a “buy” rating and set a $60.00 price objective on shares of Amedisys in a research note on Friday, September 15th. Benchmark upgraded Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective on the stock in a research note on Thursday, November 2nd. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $61.00 price objective on the stock in a research note on Friday. Royal Bank of Canada reiterated a “sector perform” rating and set a $62.00 price objective (up previously from $56.00) on shares of Amedisys in a research note on Thursday, November 9th. Finally, William Blair reiterated an “outperform” rating on shares of Amedisys in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $61.00.
The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33. The firm has a market capitalization of $1,860.00, a P/E ratio of 43.46, a PEG ratio of 1.17 and a beta of 0.71.
Institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Asset Management Americas Inc. raised its stake in Amedisys by 23.9% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 14,572 shares of the health services provider’s stock valued at $915,000 after acquiring an additional 2,812 shares during the period. Wells Fargo & Company MN raised its stake in Amedisys by 29.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after acquiring an additional 339,825 shares during the period. Castleark Management LLC bought a new stake in Amedisys in the 2nd quarter valued at $3,674,000. Assenagon Asset Management S.A. bought a new stake in Amedisys in the 3rd quarter valued at $1,212,000. Finally, Bank of New York Mellon Corp raised its stake in Amedisys by 10.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock valued at $47,375,000 after acquiring an additional 82,247 shares during the period. Institutional investors and hedge funds own 94.44% of the company’s stock.
WARNING: This piece was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/13/amedisys-amed-trading-up-6-7.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.